

*Research Article*

**Synthesis and spectral characterization of tetrahydropyrazolo pyridine analogous by a one-pot tandem MCRs using Zn-O nanocatalyst.**

**D. M. Suryawanshi**

<sup>1</sup>Rayat Shikshan Sanstha's, S.S.G.M. College, Kopergaon- 423 601, Maharashtra, India.

<sup>2</sup>Department of Chemistry, R.B.N.B. College, Shrirampur -413 709, Maharashtra, India.

Received 06 February 2019; received in revised form 05 March 2019; accepted 12 March 2019

**\*Corresponding author E-mail address:** *sdayanand77@gmail.com*

**ABSTRACT**

A various substituted aromatic aldehydes are treated with hydrazine hydrate/phenyl hydrazine, EAA, ammonium acetate results in formation of different Tetrahydropyrazolo pyridine derivatives. The conventional and non-conventional methods are used for synthesis. These derivatives are further characterized by various techniques such as NMR, IR etc. We were successfully accomplished 'Green' synthesis of tetrahydropyrazolo pyridine derivatives. Use of Zn-O nanocatalyst was found to be an efficient catalyst for heterogeneous multicomponent reaction. The catalyst was used environmentally free and yield of product is also increased. Finally catalyst is recovered. We were reused the catalysts for next reactions.

**KEYWORDS**

Phenyl hydrazine, EAA, Tetrahydropyrazolo pyridine, Zn-O nanocatalysts

## 1. INTRODUCTION

Pyrazoles are an important class of bio active drug targets in the pharmaceutical industry[1], as they are the core structure of numerous biologically active compounds.[2] For example; they exhibit ant anxiety, antipyretic, analgesic, and anti-inflammatory properties. On account of its variety of biological activity, the chemistry of pyrazoles has attracted much attention and many methods for their synthesis have been extended. Nowadays, the pyrazolone derivatives were paid much attention for their various biological activities, such as antitumor, selective COX-2 inhibitory.[3-4] Besides; they can be used as cytokine inhibitors, potent catalytic activity inhibitor of human telomerase, [5] therapeutics for kinase mediated inflammatory disorders [6] and dyes. The compounds that contain two pyrazolone rings can be used as extracting for some metal ions[7] and ligands.[8]

Pyrazolopyridines and their derivatives have a wide range of biological activities. [9,10] For example, a number of pyrazolo[3,4-*b*]pyridines exhibit biological activities, including anxiolytic (eg., trazolone), antiallergic and antiherpetic properties.[11] The research on organic light emitting diodes (OLEDs) has exploded and progressed considerably in recent years. Dipyrzolopyridines are a new class of fluorescent materials. Preliminary electroluminescence properties were reported in their polymer systems.[12-13],

Owing to their pharmacological and biological properties, 1,4-dihydropyridines (1,4-DHPs) have generated particular attention in both synthetic and medicinal research.[14] 1,4-DHPs, as a class of calcium modulators, are extensively investigated for their pharmacological activities as antioxidant, anti-tumor, anti-atherosclerosis, anti-diabetes, anti-mutagenic, anti-vasodilator, neuromodulator, hepatoprotector, neuroprotector and memory enhancer.[15] The Hantzsch synthesis, one of the most famous MCRs involving an aldehyde, two equivalents of a  $\beta$ -ketoester and a nitrogen donor such as ammonia or ammonium acetate, is most often used for the construction of 1,4-dihydropyridines.[16] Several modifications have been developed to allow for the synthesis of different 1,4-DHP derivatives.[17]


The importance of green chemistry and also the existing attraction in the design and synthesis of heterocyclic compounds through MCRs, motivated us to design a one-pot 2A+2B+C+D four component reaction for the synthesis of dipyrzolo-1,4-dihydropyridines under green reaction conditions. Although, the synthesis of dipyrzolopyridines starting from pyrazole containing building blocks have been already reported. Herein, we introduce the first example of simultaneous assembly of all three heterocyclic rings from four acyclic building blocks. We employed *in situ* preparation of the pyrazolone ring through the reaction between hydrazine and ethyl acetoacetate and subsequent reaction with aldehyde and ammonium acetate. We note that, the *in situ* formation of pyrazolone as pro nucleophiles in MCRs has already been developed.

## 2. METHODS AND MATERIALS

### 2.1 Synthesis of Zn-O Nano-Catalyst

For synthesis of nanostructure Zn-O zinc sulphate (99.9%, sd-fine chemicals, 0.2M) and oxalic acid (99.9%, sd-fine chemicals, 0.2M) has been used as a precursor material. The intermediate zinc oxalate was obtained by adding oxalic acid (0.2M) solution drop wise into zinc sulphate (0.2M) with constant stirring. The precipitate of intermediate zinc oxalate complex was washed

with distilled water (~1 lit) and dried at 80°C in heating oven. Further, intermediate powder material was decomposed at 500 °C in Muffle furnace in order to obtain nanostructured zinc oxide.




**Scheme 1.** Synthesis of Zinc Oxide (Zn-O) NPs.

## 2.2 Preparation of Pyrazole Aldehydes

### Formylation of Hydrazone


Take 45 ml DMF in dry R.B.F. with magnetic needle was taken. R.B.F. was kept in an ice bath and add 20 ml POCl<sub>3</sub> dropwise in above solution and temp. was maintained below the 100°C. After the addition of POCl<sub>3</sub> pink colored complex was appeared. Then the 0.1 moles (20gm) of hydrazine in dry beaker was dissolved in a minimum amount of DMF. These hydrazones solution as added in to the above solution by dropwise addition and temp. as maintained under 20°C. After the complete addition, solution was kept for stirring 45-60 minutes at R.T. and then stand for the over night. On the next day poured this solution on crushed ice slowly with constant stirring. Then we allowed this solution to stand for 90-120min. Then solution was filtered and recrystallized in Ethyl Alcohol (Scheme 2).



**Scheme 2.** Synthesis of Substituted Aromatic Aldehydes.

### 2.3 Synthesis of Tetrahydropyrazolo pyridine Derivatives by Non-conventional Method

The time required for synthesis of tetrahydropyrazolo pyridine derivatives by conventional method is too high. So this is time consuming process and yield also decreases. Therefore this is not affordable. In order to increase the yield of this reaction I can use the Nano-catalyst for this reaction. So the time is reduced and yield is increased. I can take a mixture of ethyl acetoacetate 1 (2 mmol) and hydrazine hydrate 2 (2 mmol) in ethanol (5mL) was magnetically stirred for 30 min at reflux condition followed by addition of aldehyde 3 (1 mmol), ammonium acetate 4 (4 mmol) and Nano catalyst. The reaction mixture was heated and then cooled to room temperature and water (20 mL) was added and the resulting mixture was stirred for 30 min. The precipitated product was filtered, washed with water and then dried under vacuum recrystallization from ethanol. Finally I observed that time is reduced almost to half. That's why this are economically important reactions by using Nano-catalyst (Scheme 3).



**Scheme 3.** Synthesis of tetrahydropyrazolo pyridine (8a-l)

## 3. RESULTS AND DISCUSSION

### 3.1 Characterization of Powdered ZnO Catalyst

#### a. X-Ray Diffraction Studies

The precipitated fine particles (ZnO) were characterized by XRD as shown in fig 1.5 The structure and their crystallite size were evaluated. The crystallite size of the non- crystalline samples was measured using Debye-Scherer formula,

$$DXRD = \frac{0.98\lambda}{\beta \cos \theta}$$

Where  $\lambda$  is the wavelength of X- ray used in  $\text{\AA}$ ,  $\beta$  is the full width at half maximum (FWHM) in radians in  $2\theta$  scale,  $\theta$  is the bragg angle,  $D_{XRD}$  is the crystallite size in nm.

The major diffraction peaks are present between 20 and 70 (2 $\theta$ ) corresponding to the Hexagonal Zn-O crystal structure. The diffraction peaks at 2 $\theta$  values of 31.65, 34.3, 36.14, 47.45, 56.43, 62.65, 67.96 and 69.09 corresponded to the (100), (002), (101), (102), (110), (103),

(112) and (201) planes of hexagonal Zn-O nanoparticles respectively (JCPDS 36-1451). 18). The average size of the ZnO nanoparticles determined from the XRD is found within 32 nm.




Figure 1. XRD pattern of the ZnO nanoparticles.

b. FTIR Spectrum of Zn-O

FTIR spectral studies shown in following Figure give information regarding the chemical bonding between Zn and O. The spectrum showed a broad peak around  $457\text{ cm}^{-1}$  and shoulders around  $545\text{ cm}^{-1}$ , which corresponds to Zn-O Nanoparticles. The remaining spectrum was relatively smooth with a few peaks of  $\text{CO}_2$ .








Figure 2. FTIR spectrum of ZnO Nanoparticles.








The thermal study of as-synthesized zinc oxalate was carried out using Thermo Gravimetric Analyser (TGA-DTA, Metler-Toledo Star System) up to 1000°C in air at the heating rate of 10 °C /min. Powder X-ray Diffractograms (XRD) were recorded on X-ray diffractometer (Rigaku-D8/Max-2200V) using CuK-Radiation with Ni-filter. The surface morphology and particle size were determined using a field emission scanning electron microscope (FESEM HITACHI S-4800).

*c. Recycling study of ZnO catalyst*

The most important property of every catalyst is that it can be reused or recycled. I can find that the Zn-O Nano-catalyst is regenerated after doing the reaction. In this work, we examined the possibility of recovery and reuse of these catalysts by use of the one-pot reactions by using Zn-O as nanocatalyst. After completion of reaction catalyst is recovered from reaction mixture by pouring reaction mixture in ethyl acetate or catalyst is recovered during reaction. Then catalyst is washed and dried. Now the catalyst is ready to reuse.

**Table 1:** Synthesized Substituted Aromatic Aldehydes.

Entry	Comp.	Substituted Aromatic Aldehydes	Molecular Formula	Molecular Weight	Melting Point (°C)	Yield (%)
1	4a		C <sub>16</sub> H <sub>13</sub> N <sub>2</sub> O	249.31	120	88
2	4b		C <sub>16</sub> H <sub>13</sub> N <sub>2</sub> O	249.31	120	91
3	4c		C <sub>14</sub> H <sub>11</sub> N <sub>2</sub> SO	255.31	122	78
4	4d		C <sub>14</sub> H <sub>11</sub> N <sub>2</sub> SO	255.31	122	90

<b>5</b>	4e		$C_{16}H_{10}Cl_2N_2FO$	4336.17	180	80
<b>6</b>	4f		$C_{16}H_{12}ClN_2O$	286.06	140	86
<b>7</b>	4g		$C_{17}H_{15}N_2O$	263.31	152	85
<b>8</b>	4h		$C_{17}H_{15}N_2O$	263.31	152	89
<b>9</b>	4i		$C_{16}H_{12}FN_2O$	267.09	138	86
<b>10</b>	4j		$C_{16}H_{12}FN_2O$	267.09	138	86
<b>11</b>	4k		$C_{10}H_6ClNO$	191.61	148	88

**Table 2.** Synthesis of tetrahydropyrazolo pyridine derivatives (8a-l).

Aldehydes	Product	Molecular Formula	Molecular Weight	M.P. (°C)	Yield (%)
4a	8a	C <sub>24</sub> H <sub>21</sub> N <sub>7</sub>	407.47	238	80
4b	8b	C <sub>36</sub> H <sub>29</sub> N <sub>7</sub>	559.66	218	70
4c	8c	C <sub>34</sub> H <sub>27</sub> N <sub>7</sub> S	565.2	140	78
4d	8d	C <sub>15</sub> H <sub>15</sub> N <sub>5</sub>	265.31	188	74
4e	8e	C <sub>22</sub> H <sub>19</sub> N <sub>7</sub> S	413.5	192	82
4f	8f	C <sub>24</sub> H <sub>19</sub> ClFN <sub>7</sub>	459.14	284	75
4g	8g	C <sub>36</sub> H <sub>28</sub> ClN <sub>7</sub>	594.11	210	71
4h	8h	C <sub>25</sub> H <sub>23</sub> N <sub>7</sub>	421.5	216	79
4i	8i	C <sub>37</sub> H <sub>31</sub> N <sub>7</sub>	573.69	222	81
4j	8j	C <sub>24</sub> H <sub>20</sub> FN <sub>7</sub>	425.18	242	71
4k	8k	C <sub>36</sub> H <sub>28</sub> FN <sub>7</sub>	577.65	242	74
4l	8l	C <sub>18</sub> H <sub>15</sub> ClN <sub>6</sub>	350.8	248	78

*3.2 Spectral analysis of synthesized Tetrahydropyrazolo pyridine derivatives*

**Compound 8a:-** (Table 5, entry 1): M.F. C<sub>24</sub>H<sub>21</sub>N<sub>7</sub>; M.P. 238°C; IR: 3160.1, 3150, 3100, 1592.2, 1500, 1026.02 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ: 2.0 (s, 6H), 7.3-8 (m, 10H), 8.7 (s, 1H), 9.2 (s, 1H), 10.2 (s, 1); MS: m/z (%): 407.1.

**Compound 8b:-** (Table 5, entry 2): M.F. C<sub>36</sub>H<sub>29</sub>N<sub>7</sub>; M.P. 218°C ;IR: 3125.01, 3138, 1502.2, 1500, 995.1 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ: 3.1 (s, 6H), 7.1-7.9 (m, 21H), 7.8 (s, 1H), 10.2 (s, 1H), 10.8 (s, 1H); MS: m/z (%): 559.25.

**Compound 8c:-** (Table 5, entry 3): M.F. C<sub>34</sub>H<sub>27</sub>N<sub>7</sub>S; M.P. 140°C; IR: 3200, 1550, 1598, 992.01 <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ: 3.4 (s, 6H), 7.2-8.0 (m, 19H), 7.2 (s, 1H), 9.8 (s, 1H), 10.2 (s, 1H); MS: m/z (%): 565.20.

**Compound 8d:-** (Table 5, entry 4): M.F. C<sub>15</sub>H<sub>15</sub>N<sub>5</sub>; M.P. 188°C; IR: 3248, 1532, 1400, 965 cm<sup>-1</sup>



$^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 3.3 (s, 6H), 7.3-8.0 (m, 5H), 7.7 (s, 1H), 8.7 (s, 1H), 10.3 (s, 1H); MS: m/z (%): 265.13.

**Compound 8e**:- (Table 5, entry 5): M.F.  $\text{C}_{22}\text{H}_{19}\text{N}_7\text{S}$ ; M.P.  $192^\circ\text{C}$ ; IR: 3120.03, 1596.09, 1500, 1211.95, 1053.17, 685.48  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 2.3 (s, 6H), 7.1-8.0 (m, 9H), 8.0 (s, 1H), 8.9 (s, 1H), 10.2 (s, 1H); MS: m/z (%): 413.14.

**Compound 8f**:- (Table 5, entry 6): M.F.  $\text{C}_{24}\text{H}_{19}\text{ClFN}_7$ ; M.P.  $284^\circ\text{C}$ ; IR: 3108.01, 3008, 1582.02, 1500, 920  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 3.09 (s, 6H), 6.1-9.0 (m, 9H), 7.2 (s, 1H), 8.3 (s, 1H), 10.1 (s, 1H); MS: m/z (%): 459.14.

**Compound 8g**:- (Table 5, entry 7): M.F.  $\text{C}_{36}\text{H}_{28}\text{ClN}_7$ ; M.P.  $210^\circ\text{C}$ ; IR: 3192.2, 3038.1, 1590, 1520, 994  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 2.3 (s, 6H), 7.2-7.9 (m, 10H), 7.9 (s, 1H), 7.9 (s, 1H), 10.2 (s, 1H); MS: m/z (%): 593.21.

**Compound 8h**:- (Table 5, entry 8): M.F.  $\text{C}_{25}\text{H}_{23}\text{N}_7$ ; M.P.  $216^\circ\text{C}$ ; IR: 3092, 3030.20, 1584.21, 1518.2, 981.20  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 3.9 (s, 6H), 7.3-8.3 (m, 10H), 6.10 (s, 1H), 8.3 (s, 1H), 10.1 (s, 1H); MS: m/z (%): 421.20.

**Compound 8i**:- (Table 5, entry 9): M.F.  $\text{C}_{37}\text{H}_{31}\text{N}_7$ ; M.P.  $222^\circ\text{C}$ ; IR: 3145, 3059.24, 1595.34, 1495.62, 750  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 2.4 (s, 6H), 2.3 (s, 3H), 7.1-7.8 (m, 10H), 7.9 (s, 1H), 8.0 (s, 1H), 10.21 (s, 1H); MS: m/z (%): 573.26.

**Compound 8j**:- (Table 5, entry 10): M.F.  $\text{C}_{24}\text{H}_{20}\text{FN}_7$ ; M.P.  $242^\circ\text{C}$ ; IR: 3185.1, 1536.96, 1218.22, 837.54  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 2.0 (s, 6H), 7.3-8 (m, 10H), 8.7 (s, 1H), 9.2 (s, 1H), 10.2 (s, 1H); MS: m/z (%): 525.18.

**Compound 8k**:- (Table 5, entry 11): M.F.  $\text{C}_{37}\text{H}_{28}\text{FN}_7$ ; M.P.  $242^\circ\text{C}$ ; IR: 3120.21, 2902, 1568, 1533.33, 890.99  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 3.9 (s, 6H), 6.9-8.0 (m, 10H), 7.7 (s, 1H), 8.9 (s, 1H), 10.9 (s, 1H); MS: m/z (%): 577.24.

#### 4. CONCLUSION

The procedure and techniques employed for characterization of different Tetrahydropyrazolo pyridine derivative by elemental analysis, IR, and  $^1\text{H}$ -NMR spectroscopy. We were successfully accomplished 'Green' synthesis of tetrahydropyrazolo pyridine derivatives. Use of nano catalyst Zn-O nano crystals was found to be an efficient catalyst for heterogeneous this Multicomponent reaction. The catalyst used was environmentally free and yield of product was also increased. Finally catalyst is recycled.

#### 5. ACKNOWLEDGEMENT

The authors are grateful to the Principal, S.S.G.M. College, Kopergaon for providing necessary laboratory facilities and Department of Chemistry, Savitribai Phule Pune University, for providing laboratory facilities for carried out spectrum.

#### 6. REFERENCES

1. Domling, A.; Ugi, I. *Angew. (1993) Chem. Intl. Ed.*, 32, 563.
2. McDonald, E.; Jones, K.; Brough, P. A.; Drysdale, M. J.; Workman, P. (2006) *Curr. Top. Med. Chem.* 6, 1193.

3. Park, H. J.; Lee, K.; Park, S. J.; Ahn, B.; Lee, J. C.; Cho, H. Y.; Lee, K. I. (2005) *Bioorg. Med. Chem. Lett.* **15**, 3307.
4. Clark, M. P.; Laughlin, S. K.; Laufersweiler, M. J.; Bookland, R. G.; Brugel, T. A.; Golebiowski, A.; Sabat, M. P.; Townes, J. A.; VanRens, J. C.; Djung, J. F.; Natchus, M. G.; De, B.; Hsieh, L. C.; Xu, S. C.; Walter, R. L.; Mekel, M. J.; Heitmeyer, S. A.; Brown, K. K.; Juergens, K.; Taiwo, Y. O.; Janusz, M. J. J. (2004) *Med. Chem.* **11**, 2724.
5. Yasutaka, K.; Narie, S.; Mieko, S. M.; Hiromu, M.; Kimiko, M. M.; (2004) *Biochem. Biophys. Res. Commun.* **4**, 1351.
6. Clark, M. P.; Bookland, R. G. (2005) *Expert Opin. Ther. Pat.* **11**, 1617.
7. Takeishi, H.; Kitatsuji, Y.; Kimura, T.; Meguro, Y.; Yoshida, Z.; Kihara, S. (2001) *Anal. Chim. Acta.*, **1**, 69.
8. Abdel-Latif, S. A.; (2001) *Synth. React. Inorg. Metal-organic Chem.*, **8**, 1355.
9. Yu, G.; Mason, H.; Wu, X.; Wang, J.; Chong, S.; Dorough, G.; Henwood, A.; Pongrac, R.; Seliger, L.; He, B.; Normandin, D.; Adam, L.; Krupinski, J.; Macor, J. (2001) *J. Med. Chem.*, **44**, 1025.
10. Liu, C.; Li, Z.; Zhao, L.; Shen, L. (2001) *Arkivoc*, (ii), 258.
11. Chen, Y. L. *WO Pat.* (1995) *Chem. Abstr.*, **124**, 232447.
12. Tao, Y. T.; Balasubramaniam, E.; Danel, A.; Tomasik, P. (2000) *Appl. Phys. Lett.*, **77**, 933.
13. Tao, Y. T.; Chuen, C. H.; Ko, C. W.; Peng, J. W. (2002) *Chem. Mater.*, **14**, 4256.
14. Kappe, C. O. (2000) *Eur. J. Med. Chem.*, **35**, 1043.
15. Varache-Lembewge, M.; Nuhrich, A.; Zemb, V.; Devaux, G.; Vacher, P.; Vacher, A. M.; Dufy, B. 1996) *Eur. J. Med. Chem.*, **31**, 547.
16. Hantzsch, A. (1881) *Ber. Dtsch. Chem. Ges.*, **14**, 1637.
17. Ghosh, S.; Saikh, F.; Das, J.; Pramanik, A. K. (2013) *Tetrahedron Lett.*, **54**, 58.